All Activity

Excellent article. Very interesting to read. I really love to read such a nice article. Thanks! keep rocking. Top 10 cafes bangkok

Such a great breakdown of the pillars! If you want to see this practically, find a BaZi Calculator and pull up your BaZi Chart. It is amazing to see your destiny elements laid out clearly without any guesswork. My BaZi reading gave me so much clarity on my life purpose and the direction I need to take!

A beautiful Aerocity Escort from our agency is all you need to turn a dull evening into a festival. Our handpicked VIP models and air hostesses provide private companionship that arouses passion and offers boundless pleasure. They excel at engaging conversation and intimate moments, making you feel like the center of their universe. Contact us now to book a session that promises unbelievable ecstasy and total relaxation.

A Republican congressman who plans to imminently file legislation to federally regulate hemp-derived products in place of a ban that’s currently scheduled to go into effect later this year says the plan faces opposition from a coalition of strange bedfellows that includes sectors of the alcohol industry, marijuana businesses and cannabis legalization opponents. Rep. Andy Barr (R-KY) said during a Zoom meeting with members of the group Hemp Industry & Farmers of America (HIFA) on Thursday that his bill will create “a regulatory and tax framework” that “would provide a lifeline and a…durable legal pathway for this marketplace,” according to a transcript obtained by Marijuana Moment. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, Trump signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. Barr said the planned recriminalization of hemp THC products would “jeopardize the existing crop that is in storage right now” after having been grown by farmers and would upend “future opportunities to cultivate this this crop.” “So that’s why we need this legislation to establish a regulatory framework and create a level playing field with other similar products, especially in the drink category,” he said, according to the meeting transcript. “We want to create kind of a level playing field with other adult beverages so that farmers will have certainty that they can sell into a mature marketplace with protections that achieves both what we want it to achieve—for safety, for targeting age-appropriate consumers—but also helping our farmers all the way through.” But the effort is facing opposition not just from prohibitionist forces but also from segments of the alcohol industry as well as marijuana businesses that sell cannabis products under limited state-based licensing systems, according to the congressman. Producers of distilled spirits have an “understandable concern about competition” from hemp-derived THC drinks, Barr said. Companies in the wholesale tier of the alcohol industry could be an ally, he added, “because they want to distribute” cannabis beverages. “I think the wholesalers want a three-tier system, so we have worked to try to achieve that with, again, a level playing field where you would have exceptions for direct-to-consumer, where it would make sense that it’s on a state-by-state level,” he said. “We recognize that distilled spirits and other adult beverage groups don’t want competition. That’s natural. But what we want is regulation and tax… We want a level playing field. Competition and choice is something I believe in. And giving consumers choices. Competition’s a good thing… You’re looking at one of the most adamant defenders of the bourbon industry. I’m co-chairman of the Congressional Bourbon Caucus. I don’t think you have to choose. I think you can be an advocate of both hemp products and Kentucky bourbon. So the issue is a level playing field.” “Then you have the prohibitionists,” the congressman said. “And they’re just there, and they may not be persuadable, but they exist.” “And then finally, there’s another category out there, and that’s the marijuana industry that views this as competition as well,” Barr said, per the transcript of the meeting. “They will want to push the industry into specialized dispensaries. My view is that that is not a level playing field. Maybe that’s appropriate for the marijuana industry, but I don’t believe that’s appropriate for this hemp-derived product industry.” Join HIFA & Rep. Andy Barr on TODAY at 3:45 PM ET to discuss the bipartisan LAWFUL HEMP PROTECTION ACT – protecting a $50B+ industry & 475,000+ jobs. Register: https://t.co/KMo9TbD9Y9 pic.twitter.com/S4w7bdTEAR — Hemp Industry & Farmers of America (@hifa_health) May 14, 2026 Barr’s forthcoming bill, which is titled the “Lawful Hemp Protection Act” in draft versions that Marijuana Moment has seen, would institute age limits labeling requirements for hemp products, subject to Food and Drug Administration (FDA) oversight. There would also be taxes on hemp products administered by the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau (TTB). Meanwhile, White House officials recently provided Barr’s office with feedback on pending legislation to create a regulatory framework for hemp. Last month, Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to the congressman’s office. “We appreciate your work to advance the policy of” an executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products, the staffers wrote in a letter to the congressman. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” the White House officials said, according to a social media post containing a screenshot of the letter. “We are available for discussion and further technical assistance.” The attachment with the administration’s proposed legislative text has not been publicly released, and the White House and Barr’s office did not respond to Marijuana Moment’s requests for further details. At Thursday’s meeting with hemp business representatives, the congressman said there’s “tremendous opportunity in agriculture, in farming, and in this industry generally,” according to the transcript. “I come from Central Kentucky. All four of my grandparents were born and raised in central Kentucky. I was raised in central Kentucky. And once upon a time, that was the burley tobacco capital of the world. Since the decline in tobacco production, our farmers have been looking for alternatives. And industrial hemp and hemp-derived products has created a huge marketplace and tremendous opportunity. And in the consumer marketplace, this has created some choices for consumers. I look forward to working with the industry to provide some stability and certainty so that this industry can be viewed properly as a mature industry, so that there’ll be some durability to the law and decrease the uncertainty that currently exists, so that this market can thrive.” Barr also said cannabis products can provide a safer alternative to prescription medications, especially for military veterans. “To the extent we can promote opioid alternatives or opioid avoidance and help veterans with anxiety or sleep deprivation or insomnia or post-traumatic stress, that’s exactly what we want to do, is to create those options for our veterans to take care of them,” he said. “We think this is a great option for our veteran community.” HIFA officials on the call said they expect Barr’s bill to be filed within the next week, though the expected timeline for the legislation has already shifted back a few times over the past several weeks as Barr has engaged stakeholders, tweaked draft provisions and sought initial cosponsors to join him in introducing the proposal. The House of Representatives recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect in November. Trump last month pushed congressional lawmakers to take action to amend the currently scheduled hemp ban, which he suggested threatens to federally recriminalize full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” the president said in a Truth Social post on Thursday, the same day his administration announced it is moving forward to reschedule marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Major retailer Target, meanwhile, recently moved to expand its sales of hemp THC drinks into more states. The Wine & Spirits Wholesalers of America (WSWA), for its part, said the House’s failure to include provisions to delay or alter the ban on hemp THC products was a “missed opportunity.” “A ban will not remove these products from the market—it will push consumers toward unregulated, online channels with no age verification, no product standards and no accountability,” Dawson Hobbs, executive vice president of government affairs for WSWA said. The post GOP Congressman Says His Hemp Regulation Bill Faces Opposition From Alcohol, Marijuana And Prohibitionist Groups appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Studies “consistently show” that the non-intoxicating marijuana component CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans, according to a new systemic review of the scientific literature. Numerous studies have investigated how cannabis and its constituents may impact the symptoms and progression of cancer. The new paper published in the journal Frontiers in Veterinary Science examined that preclinical research, which generally indicates that CBD may “inhibit cell proliferation and migration, while inducing apoptosis in various human tumor cells.” How cannabidiol affects canines has been less rigorously studied compared to humans. That’s despite the fact that the cannabinoid “has been shown to be safe and well-tolerated in dogs, supporting its potential clinical use,” the authors, who are affiliated with the University of Chile, said. They wrote that since 2015, “some studies have been conducted evaluating CBD in different types of canine cancer,” but “no comprehensive review of these findings has been performed.” “For this reason, we conducted a systematic review to compile the existing evidence on the anticancer effects of CBD in dogs,” they said, adding that their analysis determined that preclinical studies, largely based on cellular models, often focus on “lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma.” “These studies consistently show that CBD exerts antiproliferative and proapoptotic effects, in some cases by modulating intracellular signaling pathways,” the review said. “Additionally, some studies have evaluated the combination of CBD with other drugs, reporting both synergistic and antagonistic effects.” “Overall, these findings highlight the potential of CBD as an anticancer agent across different cancer types. However, further studies are required to better elucidate the mechanisms underlying the effects of CBD and to standardize concentrations and formulations, enabling reliable, comparable results and the development of clinical studies evaluating the role of CBD in canine oncology.” The study review builds upon a sizable body of research on the therapeutic potential of cannabis in cancer treatment. For example, another recent scientific review found that CBD “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties. Scientists explored CBD’s effect on many types of cancer—including some of the most aggressive ones, such as glioblastoma, which affects the brain. They also noted it can help suppressing the growth and metastasis of other cancers, including breast, lung, colorectal, ovarian and prostate, among others. In 2025, a paper published in the journal Pharmacology & Therapeutics, assessed a range of clinical and preclinical findings that the efficacy of chemotherapy drugs can be enhanced by medical marijuana. In a sign of greater acceptance of medical applications of cannabis, President Donald Trump’s choice to serve as the next White House drug czar has called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t object to legalization, even if she might not personally agree with the policy. Also last year, a study found that “patients with cancer using cannabis report significant improvements in cancer-related symptoms.” With respect to canine research, a case study in the journal Veterinary Medicine and Science published last year suggests that very small doses of the psychedelic LSD appeared to ease a dog’s severe separation anxiety, reducing destructive behavior and shortening the duration of vocalizations. the National Animal Supplement Council (NASC) promoted a study in 2024 that it said shows CBD is “safe for long-term use” in dogs—a significant finding given emerging research that cannabis can effectively treat conditions such as anxiety and certain skin diseases among canines. Another 2024 case study found that cannabis appears to be a “viable alternative” treatment option for dogs suffering from a common skin disease, especially if they experience adverse side effects from conventional steroid therapies. The post CBD Holds Potential As An ‘Anticancer Agent’ For Dogs, New Scientific Review Concludes appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Sen. John Fetterman (D-PA) is giving some across-the-aisle credit to President Donald Trump for his administration’s moves to federally reschedule marijuana and accelerate therapeutic access to psychedelics. “I think we could all agree [on] everything that President Trump has done about liberalizing marijuana and psychedelics and now too,” Fetterman said in an interview published by Reason on Wednesday. “I really am very, very libertarian in a lot of ways and for those circumstances,” the senator said. “If you check my record, I’ve been for legal weed for forever in that. Politically, that was toxic or certainly not popular. And also psychedelics too.” “As a libertarian I don’t judge or knock anyone for whatever that they knock their edge off to just make it through in this world,” he said, pointing to his opposition to a crackdown on the nicotine product Zyn, an issue on which he has clashed with other Democrats. “I absolutely support Zyn and those things as long as it’s legal, safe too,” Fetterman said. “I think that’s important. That’s a choice that every American of legal age deserves to have, and to participate in a way that doesn’t turn them into a criminal or judge [them] for those things—make it as safe as possible.” The senator said the right to choose to relax with whatever substances one wants, as long as it doesn’t hurt anybody else, is “sacred.” “Whatever that is. A glass of wine or scotch or sip a little weed, whatever, sitting in front of the fire pit in your backyard.” he said. “Whatever that is. I think your path for wellness, psychedelics, whatever. I think it all should be legal without judgment and without punishment or a criminal record.” “I’ve been very consistent about that and sharing those things,” Fetterman, who has championed cannabis reform since he served as Pennsylvania’s lieutenant governor, said. “So I do hope it continues to liberalize for that, overall.” The Department of Justice last month formally moved state-regulated medical marijuana products from Schedule I of the Controlled Substances Act to Schedule III. A hearing scheduled to begin next month will consider the issue of broader cannabis rescheduling. Also last month, Trump signed executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics. Shortly thereafter, the Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. Fetterman, for his part, has criticized Pennsylvania GOP lawmakers for holding up marijuana legalization as neighboring states like Ohio move forward with the policy change. Last year, the senator’s campaign launched a petition supporting federal marijuana legalization. He previously criticized President Joe Biden for excluding military-level cannabis policy violations from his mass marijuana pardons. The post Fetterman Praises Trump’s Marijuana And Psychedelics Reform Moves appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Anti-rescheduling provision advances in Congress; Lawmaker: “a lot” of colleagues smoke marijuana; LA medical cannabis in hospitals; Psychedelics poll Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The House of Representatives passed amendments to allow military veterans to get medical cannabis recommendations from their Department of Veterans Affairs doctors and to raise awareness about the benefits of psychedelic therapies. The House Appropriations Committee approved a spending bill containing a provision to block marijuana rescheduling action by the Department of Justice—but also including a longstanding rider protecting state medical cannabis laws from federal interference. Rep. Ilhan Omar (D-MN) said “there are a lot of people who smoke cannabis in Congress”—adding that “advocacy for legalizing doesn’t necessarily mean that you are a user.” “So everybody can be an advocate for legalizing it, because we understand that it is not okay for us to spend the billions of dollars we do now on incarcerating people for smoking a joint.” The Louisiana House Health and Welfare Committee approved a Senate-passed bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals, subject to certain limitations. A new poll of U.S. voters shows there’s been a “striking increase” in support for legal and regulated therapeutic access to psychedelics as well as expanded research exploring their medical potential over the last two years. / FEDERAL A U.S. Bankruptcy Court judge approved recognition of insolvency proceedings for the Cannabist Co. Sen. Susan Collins (R-ME) asked Federal Bureau of Investigation Director Kash Patel and Drug Enforcement Administration Administrator Terrance Cole about what their agencies are doing to address Chinese-linked illegal marijuana operations in Maine and other states during a Senate Appropriations Committee hearing. The House bill to regulate hemp products got one new cosponsor for a total of six. / STATES California’s attorney general touted enforcement actions against an unlicensed marijuana business. A Virginia delegate said he is cautiously optimistic that Gov. Abigail Spanberger (D) will allow his recreational marijuana sales legalization bill to take effect even after lawmakers rejected her proposed amendments. Michigan regulators are opening a second public comment period on proposed changes to marijuana rules. Colorado regulators published guidance on marijuana fee setting. Nevada regulators published a demographic study of the state’s cannabis industry. A member of the Oklahoma Medical Marijuana Executive Advisory Council was removed from her role. The New Jersey State Board of Medical Examiners temporarily suspended the license of a doctor who allegedly disregarded requirements for authorizing medical cannabis. New York regulators are recruiting participants for a study on CBD and THC in treating inflammatory bowel disease. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don\’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL The Victoria, Australia Legislative Council approved a to codify the state’s approach to issuing cautions for marijuana as an alternative to arrests. / SCIENCE & HEALTH A study found that “CBD treatment was associated with statistically and clinically significant [quality of life] improvement across multiple domains in children with drug-resistant epilepsy” and that “seizure frequency reduction was observed in the majority of patients.” A case series concluded that “psilocybin may enhance motor recovery and sensory integration in incomplete spinal cord injury through amplification of existing neural pathways and warrant controlled clinical trials.” / ADVOCACY, OPINION & ANALYSIS The Pennsylvania Democratic Party tweeted, “Stacy Garrity said the quiet part out loud: if she’s elected, recreational marijuana legalization in Pennsylvania isn’t happening. While Governor Josh Shapiro is fighting to keep revenue in Pennsylvania instead of losing it to neighboring states, she’s doubling down on an out-of-touch agenda that ignores the broad bipartisan support for legalization. PA is not her priority — her toxic agenda is.” / BUSINESS Glass House Brands Inc. reported quarterly net revenue of $40.5 million and a net loss of $17 million. Auxly Cannabis Group Inc. reported quarterly net revenue of C$39.8 million. Trulieve Cannabis Corp. is seeking shareholder approval to redomicile the company from British Columbia, Canada to Delaware. Stiiizy is being sued for allegedly concealing tracking tools on its website to monitor shopping habits and then selling the data to brokers. / CULTURE Opry Entertainment Group named Señorita as the official THC beverage partner for the Grand Ole Opry and other venues. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Amendment to let military vets get medical cannabis approved at VA passes (Newsletter: May 15, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Drift Boss is an infinite game; there is no definitive endpoint. You may continue driving indefinitely, provided you remain on the course.

In the popular video game Run 3, your objective is to cover as much ground as possible in order to reach the finish line. This platform game is fast-paced and features hundreds of different levels for players to discover.

Geometry dash subzero takes the fast-paced action of the original Geometry Dash and drops it into a smooth, cold world. This game is great for people who like strong reaction-based platformers with a steady beat and cold graphics. Subzero has stylish graphics, frozen levels, and electrifying beats. It challenges players to time every jump perfectly as they navigate through frozen objects and sharp spikes.

Late-night loneliness can make even the busiest city feel surprisingly empty sometimes. That is why many people quietly choose Escort Service in Mahipalpur whenever they want feminine company that feels elegant and emotionally engaging. The experience becomes more enjoyable when the companion understands how to maintain playful energy while still creating emotional ease.

Virginia’s governor has signed legislation to provide resentencing relief for people with past marijuana convictions—even after lawmakers declined to adopt her proposed amendments to the legislation that would have significantly scaled back the scope of the reform. Gov. Abigail Spanberger (D) gave final approval to the bills, HB 26 from Rozia Henson, Jr. (D), and SB 62 from Senate President Pro Tem Louise Lucas (D), on Thursday. Separately, lawmakers and advocates are awaiting the governor’s action on separate legislation to legalize recreational marijuana sales after her proposed amendments were similarly rejected by the House and Senate last month. The suggested changes to that legislation included delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The resentencing reform, meanwhile, creates a process by which people who are incarcerated or on community supervision for certain felony offenses involving the possession, manufacture, selling or distribution of marijuana will receive an automatic hearing to consider modification of their sentences. Spanberger last month had sent lawmakers suggested amendments that would have required affected persons to proactively file petitions to get the relief instead of having courts proceed automatically. The Senate and House of Delegates, however, declined to take up the proposal, effectively rejecting it and sending the original legislation back to Spanberger’s desk. Henson, the sponsor of the House version of the bill, had said he was willing to accept the governor’s changes even if he worried that it would mean that some people with cannabis convictions would “fall through the cracks simply because they lacked a lawyer or did not know to ask.” The full legislature did not agree to the changes, however, and now HB 26 and SB 62 as originally passed have been enacted into law. The relief will apply to people whose convictions or adjudications are for conduct that occurred prior to July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect. State and local corrections officials will be required to identify and notify eligible people of their rights for resentencing relief and then work with courts to schedule hearings automatically. Henson said last month that the resentencing legislation was “built for the people still paying the price for something Virginia has since made legal.” “If the commonwealth changed the law, it has an obligation to revisit the consequences still being borne by people convicted under the old one,” he said. The governor’s office claimed in a press release when she proposed her amendments that they “clarify that under no circumstances would reconsideration be allowed for violent offenses that remain illegal in Virginia—from armed burglary to firearm possession to distribution of fentanyl, heroin, and other dangerous drugs.” But Henson said that while he shares “the governor’s commitment to ensuring that violent offenders are not eligible for this relief; and that commitment is reflected in the bill itself, which already excluded individuals convicted of acts of violence under Virginia law.” Spanberger’s release last month did not make any mention of her major actual change to the bill, which is to remove its provisions for automatic relief for people with cannabis convictions. The governor’s amendment also proposed to remove deadlines for court hearings on resentencing relief. Similar legislation was approved by lawmakers last session but it was vetoed by then-Gov. Glenn Youngkin (R). Separately, Spanberger signed several other reform bills last month—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. Cannabis policy reform advocacy organizations, meanwhile, sent a letter earlier this month urging the governor to allow the adult-use marijuana sales bill to take effect. The post Virginia Governor Signs Marijuana Resentencing Bill After Lawmakers Rejected Her Amendments appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The U.S. House of Representatives has voted to let military veterans receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA)—while also approving a separate amendment focused on the therapeutic benefits of psychedelics. The cannabis proposal from Reps. Brian Mast (R-FL), Dave Joyce (R-OH) and Dina Titus (D-NV) passed by a voice vote on Thursday. If enacted into law, the amendment would prevent VA from enforcing a longstanding directive that has blocked its providers from assisting veterans with registering for state medical cannabis programs. Under current policy, VA doctors can discuss marijuana use with their patients, but they cannot fill out forms to help them actually get legal access to cannabis. As a result, veterans need to seek outside, often expensive, services from separate providers instead of being able to get assistance from their own doctors at VA. That would change under the new amendment from the co-chairs of the Congressional Cannabis Caucus, which is now attached to the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act. Mast, himself a military veteran who lost two legs during combat in Afghanistan, said on the floor ahead of the vote that medical cannabis programs “exist in a lot of states.” “And if former members of the military have doctors that they are seeing inside of the Department of Veterans Affairs, and if there’s a treatment option that they want to be considered, they want to know if it’s right for them, if it’s not right for them, if it doesn’t fit in good with other prescriptions that they have, you name it,” he said. “If they want to discuss it, they have to be able to discuss it with their doctor. That is the most important person for them to discuss it with, is their doctor.” “Whether the doctor says, ‘hey, it’s good or bad,’ that’s that’s up to the doctor to decide, but they have to be able to have that conversation,” Mast said. “I tell people often, I was in Afghanistan, lost two legs and a finger there. When I woke up in the hospital, I woke up on antidepressants, anti inflammatories, heavy sleep sedatives, a host of narcotic pain killers…and I weaned myself off of those things very quickly. That is not the case for all of my brothers and sisters. A lot of these narcotics that people are on and get placed on, especially after injuries are serious and very difficult to get off of, and leave long term, long term, lasting effects on them. There’s got to be an ability, again, for people inside the system to have that conversation with their doctor about whether that’s right.” Titus said that “cannabis is proven to help with a wide variety of medical issues that veterans face, including pain management, PTSD and opioid addiction.” “Instead of self medicating and going outside the VA system, the veterans should be able to speak with a doctor honestly about what their options are,” she said. “Our veterans deserve the best health care they can get, and should not be left behind because the federal government lags behind the states. They need to hear their options and make their choices.” I am pleased to see that the House Rules Committee made my and @RepBrianMast's amendment to allow medical marijuana recommendations @DeptVetAffairs in order. I will continue fighting to get this provision over the finish line. Our veterans deserve the best health care that they… — Dina Titus (@repdinatitus) May 14, 2026 Joyce said the amendment “is about ensuring veterans are not denied access to treatment options that may improve their quality of life. ” “Do you want them getting advice from doctors or budtenders?” he asked. “Simple question.” “Many of our service members return home bearing invisible wounds that last long after the battlefield,” Joyce said. “Chronic pain, PTSD, traumatic brain injuries, depression and other service-connected conditions that ca, profoundly affect the quality of their lives. Some veterans’ traditional treatments have not worked. Others are searching for alternatives that may help manage pain, improve daily functioning or reduce reliance on highly addictive opioids.” The veterans medical marijuana amendment reads: “SEC. __. None of the funds appropriated or otherwise made available to the Department of Veterans Affairs in this Act may be used to enforce Veterans Health Directive 1315 as it relates to— (1) the policy stating that ‘VHA providers are prohibited from completing forms or registering Veterans for participation in a State-approved marijuana program’; (2) the directive for the ‘Deputy Under Secretary for Health for Operations and Management’ to ensure that ‘medical facility Directors are aware that it is VHA policy for providers to assess Veteran use of marijuana but providers are prohibited from recommending, making referrals to or completing paperwork for Veteran participation in State marijuana programs’; and (3) the directive for the ‘VA Medical Facility Director’ to ensure that ‘VA facility staff are aware of the following’ ‘[t]he prohibition on recommending, making referrals to or completing forms and registering Veterans for participation in State-approved marijuana programs.'” While similar proposals on veterans’ medical marijuana access have been passed by both the House of Representatives and Senate in past years, they have never been enacted into law. Last year, when the House- and Senate-passed language was left out of the final bill sent to President Donald Trump, Mast told Marijuana Moment that the exclusion was “ridiculous.” “It was a great and easy opportunity to do so, and a sensical thing to move forward—and detrimental to veterans to not do so,” he said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The current amendment comes just weeks after medical marijuana was rescheduled under federal law by the Trump administration, a major policy and political development that advocates hope could boost the chances of the veterans-focused reform being enacted this year. A separate amendment to the military and veterans spending bill that was also approved on the floor in a voice vote on Thursday seeks to raise awareness about the benefits of psychedelic and other therapies for military veterans. Sponsored by Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), who co-chair the Congressional Psychedelics Advancing Therapies Caucus, the amendment’s description says it “increases and decreases funding for the Medical and Prosthetic Research account at the Department of Veterans Affairs to emphasize the importance of the Department’s research on areas benefiting veterans such as oncology, traumatic brain injury care, psychedelic therapies, and assistive devices.” Correa noted ahead of the vote that President Donald Trump last month “signed an executive order to expedite psychedelic therapy research for depression and substance abuse disorder, specifically for veterans.” “This amendment is basically about taking care of those that have answered the call of duty to defend our country—those individuals have come back from combat with invisible wounds they still have not healed,” he said. “On a daily basis, 20 to 40 veterans take their lives commit suicide because of PTSD,” Correa said. “Many veterans have taken this treatment, and essentially been cured of PTSD… This is about treating our veterans’ invisible wounds.” Meanwhile in Congress, the House Appropriations Committee approved a bill this week containing provisions that would block Department of Justice officials from taking further steps to reschedule cannabis while continuing to protect state medical marijuana laws from federal interference. A report attached to that legislation also directs federal officials to take enforcement action against unregulated cannabinoid products that “threaten consumer safety.” Separately, that panel recently approved another spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. A new report from the Congressional Research Service details the scope and limitations of the federal marijuana rescheduling move. The post House Votes To Let Military Veterans Get Medical Marijuana Recommendations From VA Doctors appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A Louisiana House committee has advanced a Senate-passed bill to let patients with terminal and irreversible conditions use medical marijuana in hospitals. The House Health and Welfare Committee approved the legislation from Sen. Katrina Jackson-Andrews (D) in a unanimous 10-0 vote on Tuesday. Under the proposal, hospitals would have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Under an amendment adopted by a Senate committee last month, emergency or outpatient departments would be exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.” Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says. The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews told the Senate Health and Welfare Committee when the panel took up the legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Louisiana, another piece of drug policy legislation that has traction this session would create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, ibogaine and MDMA. Separately, a lawmaker recently filed a proposal that would create a new state task force to “study and develop findings and recommendations regarding the potential legalization of recreational marijuana.” At the same time, however, advocates are alarmed that lawmakers are advancing legislation that threatens to send people to jail for up to one year if they smoke marijuana within 2,000 feet of a school property—including a college campus. Another Louisiana legislator, meanwhile, recently introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Getting the bill across the finish line could prove complicated in the conservative legislature, however. Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. Photo courtesy of Mike Latimer. The post Louisiana Bill To Let Terminally Ill Patients Use Medical Marijuana In Hospitals Advances Toward Final Passage appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

There’s been a “striking increase” in support for legal and regulated therapeutic access to psychedelics as well as expanded research exploring their medical potential—with a new poll finding that voters have been “warming up” to the alternative treatment option over the last two years. As the state and federal reform movement has intensified, the University of California, Berkeley Center for the Science of Psychedelics (BCSP) on Wednesday released its second national survey on how voters view the substances, as well as their opinions about differing psychedelics policy proposals. Overall, the results show that “regulated use with clear guardrails related to safety is gaining traction, while support for unregulated access is not,” the center’s memo on the poll says. That’s based on an analysis of the survey data from 2025, which revealed a “striking increase” in voter approval of “two different kinds of policy approaches” for psychedelics as compared to a prior survey done in 2023. Support for making psychedelics available as a prescription medicine increased 12 percentage points between 2023 and 2025—growing from 29 percent to 41 percent. Similarly, support for allowing the legal, therapeutic use of psychedelics grew 10 percentage points, from 36 percent to 46 percent in the span of two years. The other policy approach that gained traction over the last two years was making it easier for scientists to study psychedelics. In 2023, just under half (49 percent) of voters said they backed that proposal; by 2025, support leaped to 63 percent. “Voters appear to be warming up to psychedelics as medical treatments accessed within regulated medical and therapeutic frameworks,” the authors of the survey report said. They added, however, that there was a notable exception, with one policy concept that curiously saw a “nonsignificant” 1 percentage point decrease in support since 2023: Decriminalization. In the latest poll, only 28 percent of voters said they backed removing criminal penalties for the personal use and possession of psychedelics—a policy that has for years enjoyed majority, often bipartisan, support when applied to marijuana. “Despite an increase in local legislation that decriminalizes personal possession, we observed only tepid support from voters for this kind of policy,” the survey report said. “The wave of support for scientific research and for other highly regulated options might indicate that many voters are curious about psychedelic substances and their effects, but have concerns about their safety and efficacy.” “One interpretation is that people could be worried about the risks—or mindful of their current and historical legal parameters and stigma—resulting in them being more supportive of psychedelics in a controlled environment,” it said. How do U.S. voters feel about psychedelics? Our latest national survey reveals growing awareness of psychedelics and strong support for scientific research, alongside caution and safety concerns. Find out more on https://t.co/cOtjJlmBFQ pic.twitter.com/cEwJ9Y7TSW — UC Berkeley Center for the Science of Psychedelics (@SciPsychedelics) May 13, 2026 Meanwhile, the researchers also found that policy views about the therapeutic use of psychedelics varied when responders were asked about their application in specific instances. For example, 48 percent said they favor regulated psychedelics access, and 38 percent said they favor removing criminal penalties for psychedelics, if the person using them is in end-of-life care. Majorities of voters also support regulated therapeutic access to psychedelics for military veterans (56 percent), people with depression (60 percent) and those experiencing addiction (54 percent). For decriminalization, support for the reform was highest for end-of-life care. Another 26 percent said they back the policy for anyone aged 21 and older, followed by veterans (22 percent), those with depression (17 percent) and people with addiction (12 percent). With respect to perceived safety of psychedelics, 37 percent of respondents said it’s either “pretty” or “extremely” safe to use the substances in a supervised setting, 20 percent said the same about the safety of psychedelics compared to tobacco and 18 percent expressed the same about its relatively safety compared to alcohol. “Our main areas of exploration—exposure to psychedelics, trust, policy changes, and stigmas and concerns—yielded findings that are relevant for the quickly evolving psychedelics policy landscape,” the report concluded. “Despite large increases in support for several policy ideas, only a single idea—making scientific research on psychedelics easier (63 percent)—had majority strong support, which we believe reflects the caution with which voters view psychedelics. We also identified some appetite for public high school education on the risks and benefits of psychedelics (35 percent ‘strong support’ and 30 percent ‘somewhat support’), further underscoring voters’ desire for information and its dissemination.” The data also reflected “widespread concern and stigma around psychedelics,” the authors wrote, noting the safety comparisons to tobacco and alcohol. Between 35 percent and 38 percent of voters also said psychedelics are “addictive” and “can cause new mental health challenges.” Additionally, while 48 percent of respondents described psychedelics users as “open-minded” and another 37 percent called them “creative,” about a quarter said people who take the plant-based medicines are “irresponsible” (24 percent) or “addicts” (24 percent). “The complex mix of perceptions and attitudes shown in these data, paired with systematic demographic variations, suggest that effective messaging strategies and public education will need to build trust with specific audiences and fill knowledge gaps,” the survey concluded. The BCSP survey involved interviews with 1,577 U.S. voters from April 16-28, 2025, with a +/-2.5 percentage point margin of error. A separate survey released by the RAND Corporation in February found that, while support for legalizing the use of psychedelics was relatively low, public opinion on the issue seemed be closely following in the footsteps of the marijuana reform movement before the first states started enacting cannabis legalization. RAND researchers also released data in January showing that nearly 10 million American adults microdosed psychedelic substances such as psilocybin, LSD or MDMA in 2025. Meanwhile, the latest survey data out of UC Berkeley is being released about a week after a bipartisan coalition of 32 members of Congress urged federal health officials to expedite ongoing reviews of psychedelic therapies. For their part, the Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) last month announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. That move followed a psychedelics executive order that President Donald Trump signed. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — HHS Secretary Robert F. Kennedy Jr. said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.” In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.” Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” Veterans Affairs Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access. Bipartisan congressional lawmakers introduced legislation this session to provide $30 million in funding annually to establish psychedelic-focused “centers for excellence” at U.S. Department of Veterans Affairs (VA) facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine. A U.S. Senate committee held a hearing last month on a bipartisan bill to promote research into the therapeutic potential psychedelics by creating a new office at VA that would advance the development innovative treatments for serious mental health conditions and assist in reviewing the scheduling status of drugs like psilocybin, ibogaine and MDMA. Former U.S. House Speaker Newt Gingrich (R-GA) has said ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options. Image courtesy of CostaPPR. The post There’s Been A ‘Striking Increase’ In Support For Psychedelic Therapy And Research In The Last Two Years, Poll Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for taking the time to discuss this, I feel strongly about it and love learning more on this topic. Making a personal brand

That is a top notch points in particular to help these fresh to blogosphere, small in addition to appropriate information… Appreciate it intended for giving this blog. Important understand document. Linen suits bangkok

This type of message always inspiring and I prefer to read quality content, so happy to find good place to many here in the post, the writing is just great, thanks for the post. 성인피시

This type of message always inspiring and I prefer to read quality content, so happy to find good place to many here in the post, the writing is just great, thanks for the post. [url=https://sinpc.clickn.co.kr/]성인피시[/url]

That you're allowed to place leaders, however is not one way links, except when they're just authorised together with regarding niche. Affordable bangkok suit tailor

Great survey, I'm sure you're getting a great response. 성인피시

A key congressional committee has voted to block the federal rescheduling of marijuana—even after the Trump administration announced last month that it is moving ahead with enacting the reform. The House Appropriations Committee on Wednesday approved a funding bill containing a provision that, if enacted, would prevent federal officials from taking further steps to carry out cannabis rescheduling. “SEC. 591. None of the funds appropriated under this Act or otherwise made available by this Act may be used to reschedule marijuana (as such term is defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act (21 U.S.C. 812).” The panel has advanced similar language in the past years as the federal government has weighed marijuana rescheduling, but those provisions were never passed into law. The Department of Justice announced last month that marijuana products regulated by a state medical cannabis license immediately moved to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An administrative hearing scheduled to begin next month will consider broader cannabis rescheduling. Because the rescheduling of medical cannabis under Acting Attorney General Todd Blanche’s order took effect immediately, it’s not clear if or how the congressional rider would impact businesses and patients who are covered by that reform. If the language is passed by the full House and Senate and makes it into an appropriations package that President Donald Trump signs into law, however, it could prevent the hearing and related action on broader marijuana rescheduling from taking place. The committee approved the Fiscal Year 2027 Commerce, Justice, Science, and Related Agencies Bill containing the anti-rescheduling provision in a 32-28 vote. It will next head to the House Rules Committee, which will prepare the legislation for floor consideration. Meanwhile, the funding bill that is advancing also contains an updated version of a longstanding rider that since 2014 has protected state medical cannabis programs from federal interference. “SEC. 531. (a) None of the funds made available under this Act to the Department of Justice may be used, with respect to any of the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, or with respect to the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico, to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana. (b) Funds made available under this Act to the Department of Justice may be used to enforce violations of 21 U.S.C. 860.” This year’s provision for the first time includes Nebraska, after advocates pointed out the state was omitted from previously enacted appropriations legislation even though voters there approved medical cannabis legalization in 2024. The latter subsection of the medical cannabis rider has never been enacted before, and it seeks to stipulate that the Justice Department can still enforce a section of U.S. code that calls for increased penalties for distributing cannabis within 1,000 feet of an elementary school, vocational school, college, playground or public housing unit. Separately, the bill also includes another longstanding rider that protects state hemp research programs from federal interference. “SEC. 530. None of the funds made available by this Act may be used in contravention of section 7606 (‘‘Legitimacy of Industrial Hemp Research’’) of the Agricultural Act of 2014 (Public Law 113–79) by the Department of Justice or the Drug Enforcement Administration.” Meanwhile, the committee report attached to the spending bill also contains a number of cannabis-related provisions. It calls on the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to address the “proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids” and that “threaten consumer safety.” “Intoxicating Cannabinoids.—The Committee is concerned by the proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids. The Committee directs the DEA, in coordination with the FDA Office of Inspections and Investigations, to take appropriate enforcement actions against those whose products threaten consumer safety and fail to meet the statutory definition of section 10113 of Public Law 115–334 and section 781 of Public Law 119–37. The Committee further directs the DEA to report on these efforts and any resources necessary to enforce the controlled substance laws and regulations of the United States not later than 90 days after the enactment of this Act.” While the provision doesn’t use the word “hemp,” it cites statutes covering the crop and appears responsive to widespread sales of products derived from it after they became legal under the 2018 Farm Bill. Congress has since passed, however, and President Donald Trump has signed, new legislation that will broadly recriminalize hemp THC products starting in November. The new appropriations report attached to the bill also calls on the Department of Justice to take action against “money laundering schemes” tied to Chinese-connected illegal marijuana grow operations within the U.S. “Chinese Communist Party (CCP) Money Laundering.—The Committee directs the Department to utilize funds directed to anti-money laundering programs to investigate potential money laundering schemes involving CCP-connected marijuana businesses and entities providing financial services to these businesses.” Finally, the report notes that funding is being set aside for the Bureau of Prisons (BOP) to monitor wastewater to detect use of synthetic cannabinoids and other drugs by incarcerated people. “Wastewater Surveillance Pilot.—The Committee provides $8,500,000 to BOP to carry out a pilot program using a wastewater surveillance system to monitor the prevalence of infectious diseases—including Hepatitis C, HIV, tuberculosis, and respiratory pathogens—as well as the use of covered drugs, including fentanyl, nitazenes, and other synthetic opioids, methamphetamine, synthetic cannabinoids, and other controlled substances, among the incarcerated population at not fewer than six Federal correctional institutions. Sites will be selected to ensure representation across security classification levels, geographic regions of the United States, and institutional population sizes. Not later than 180 days after the completion of the pilot program, BOP shall submit a report detailing findings regarding the prevalence of infectious diseases and covered drug use at participating institutions, along with recommendations for legislative or administrative action.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Congress, the House is expected to consider an amendment this week to let military veterans receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA) Separately, the House Appropriations Committee approved a spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. A new report from the Congressional Research Service details the scope and limitations of the federal marijuana rescheduling move. The post Congressional Committee Votes To Block Marijuana Rescheduling, Even As Trump Administration Moves Forward With The Reform appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Wonderful posting, Thanks a ton to get spreading The following awareness. Wonderfully authored posting, doubts all of blog owners available precisely the same a higher standard subject material just like you, online has got to be improved site. I highly recommend you stay the best! 5000 baht suit

I have read all the comments and suggestions posted by the visitors for this article are very fine,We will wait for your next article so only.Thanks! How to start your personal brand

A lawmaker who helps to lead the Congressional Cannabis Caucus says there are “a lot” of fellow legislators on Capitol Hill who secretly smoke marijuana. “I think there are a lot of people who smoke cannabis in Congress,” Rep. Ilhan Omar (D-MN) said on Wednesday. She added, however, that legalization is an important policy issue that should appeal broadly beyond just those who consume marijuana. “Advocacy for legalizing doesn’t necessarily mean that you are a user,” the congresswoman told TMZ. “So everybody can be an advocate for legalizing it, because we understand that it is not okay for us to spend the billions of dollars we do now on incarcerating people for smoking a joint.” The TMZ reporter also asked Omar about the federal government’s recent move to reschedule marijuana, noting that she and President Donald Trump don’t often agree on policy issues. “I think any step forward is a good step, but we need to go farther than where we are at right now,” she said. “We’re excited that the fact that he is paying attention to this issue,” Omar said. “But it is time, like I said, for the federal government to fully legalize. We already have so many states that have already legalized, and I think it is just really important for the whole country to have cannabis be legal.” As to whether Trump will ultimately come around to back broader marijuana legalization, the congresswoman said, “I am true to the belief that cannabis should be legal. I don’t know if he’s there yet, but I love to get him there.” “We need to continue building the coalition. We need to continue to have people speak for the president. He has the power. Congress has the power, and it’s us to come together and get this done.” Omar made the comments in an interview after speaking at a press conference with marijuana legalization advocates and other lawmakers who support reform. At that event, the congresswoman said it’s “about damn time Congress caught up with where the American people are” on cannabis legalization. “Millions of people across this country agree that cannabis should be legal. People understand that the old approach has failed. They understand that adults should not carry criminal records for possessing cannabis,” she said. “They understand that we should be investing in education and economic opportunity, not mass incarceration.” But she also argued that “legalization alone is not enough.” “If we legalize cannabis and simply allow large corporations to make huge profits while the very communities destroyed by the War on Drugs are left behind, then we have failed. Cannabis reform must be about justice and repair,” Omar said. “That means expunging the records of people arrested for nonviolent cannabis offenses. It means reinvesting in communities that were targeted for decades by discriminatory policies, and it means ensuring working class people small businesses and entrepreneurs have a real opportunity in participating in this new economy.” Meanwhile in Congress, the House is expected to consider an amendment this week to let military veterans receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA) The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved a bill last month containing provisions that would block federal officials from taking further steps to reschedule cannabis. Separately, the House Appropriations Committee approved a spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. A new report from the Congressional Research Service details the scope and limitations of the federal marijuana rescheduling move. The post ‘There Are A Lot Of People Who Smoke Cannabis In Congress,’ Lawmaker Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net